These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 29434143)

  • 21. The feasibility study of Carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias.
    Minegishi Y; Kuribayashi H; Kitamura K; Mizutani H; Kosaihira S; Okano T; Seike M; Azuma A; Yoshimura A; Kudoh S; Gemma A
    J Thorac Oncol; 2011 Apr; 6(4):801-7. PubMed ID: 21336181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
    Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA
    Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of nanoparticle albumin-bound paclitaxel plus carboplatin in non-small lung cancer patients with malignant pleural effusion.
    Koyama N; Watanabe Y; Iwai Y; Miwa C; Nagai Y; Aoshiba K; Nakamura H
    Neoplasma; 2018; 65(1):132-139. PubMed ID: 29322797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study.
    Dechow T; Riera-Knorrenschild J; Hackanson B; Janssen J; Schulz H; Chiabudini M; Fischer von Weikersthal L; Budweiser S; Nacke A; Taeuscher D; Welslau M; Potthoff K
    Cancer Med; 2021 Nov; 10(22):8127-8137. PubMed ID: 34668662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
    Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M;
    Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
    Tanaka H; Hasegawa Y; Makiguchi T; Okumura F; Tabe C; Shiratori T; Ishioka Y; Itoga M; Taima K; Yokouchi J; Hatayama Y; Aoki M; Tasaka S
    Clin Lung Cancer; 2021 Jan; 22(1):42-48. PubMed ID: 33158764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
    Tamiya M; Tamiya A; Suzuki H; Taniguchi Y; Katayama K; Minomo S; Nakao K; Takeuchi N; Matsuda Y; Naito Y; Shiroyama T; Okamoto N; Okishio K; Kumagai T; Atagi S; Imamura F; Hirashima T
    Invest New Drugs; 2021 Aug; 39(4):1106-1112. PubMed ID: 33544282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer.
    Fang Y; Wang L; Xia GH; Shi MQ
    Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias.
    Minegishi Y; Sudoh J; Kuribayasi H; Mizutani H; Seike M; Azuma A; Yoshimura A; Kudoh S; Gemma A
    Lung Cancer; 2011 Jan; 71(1):70-4. PubMed ID: 20493578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
    Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
    J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence.
    Adrianzen Herrera D; Ashai N; Perez-Soler R; Cheng H
    Expert Opin Pharmacother; 2019 Jan; 20(1):95-102. PubMed ID: 30439289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.
    Kenmotsu H; Yoh K; Mori K; Ono A; Baba T; Fujiwara Y; Yamaguchi O; Ko R; Okamoto H; Yamamoto N; Ninomiya T; Ogura T; Kato T
    Cancer Sci; 2019 Dec; 110(12):3738-3745. PubMed ID: 31608537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy and Safety of Carboplatin/Nanoparticle Albumin-Bound Paclitaxel Combination Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer or Recurrent Non-Small-Cell Lung Cancer Following Surgery].
    Shimabukuro I; Noguchi S; Uyama K; Torii R; Ishimoto H; Yoshii C; Tanaka F; Yatera K; Mukae H
    Gan To Kagaku Ryoho; 2018 Sep; 45(9):1305-1310. PubMed ID: 30237372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung.
    Yang JJ; Huang C; Chen GY; Song Y; Cheng Y; Yan HH; Zhou Q; Wu YL
    BMC Cancer; 2014 Sep; 14():684. PubMed ID: 25239521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxane-based Chemotherapy for Stage IV Non-Small-cell Lung Cancer in a US Community Oncology Setting.
    Weiss J; Force RW; Pugmire BA; Peterson T; Faria C; Margunato-Debay S; Patel MB
    Clin Lung Cancer; 2017 Jul; 18(4):372-380.e1. PubMed ID: 28117221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
    Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
    Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.
    Socinski MA; Langer CJ; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Zhang H; Renschler MF
    Ann Oncol; 2013 Feb; 24(2):314-321. PubMed ID: 23123509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer.
    Levy BP; Signorovitch JE; Yang H; Patterson-Lomba O; Xiang CQ; Parisi M
    Curr Oncol; 2019 Jun; 26(3):e300-e308. PubMed ID: 31285672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Tsuchiya-Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I
    Oncologist; 2020 Jun; 25(6):475-e891. PubMed ID: 31649134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.